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Hypoxia is associated with resistance to radiotherapy and chemotherapy in malignant gliomas, and it can be
imaged by positron emission tomography with 18F-fluoromisonidazole (18F-FMISO). Previous results for patients
with brain cancer imaged with 18F-FMISO at a single center before conventional chemoradiotherapy showed
that tumor uptake via T/Bmax (tissue SUVmax/blood SUV) and hypoxic volume (HV) was associated with poor
survival. However, in a multicenter clinical trial (ACRIN 6684), traditional uptake parameters were not found to
be prognostically significant, but tumor SUVpeak did predict survival at 1 year. The present analysis considered
both study cohorts to reconcile key differences and examine the potential utility of adding radiomic features as
prognostic variables for outcome prediction on the combined cohort of 72 patients with brain cancer (30
University of Washington and 42 ACRIN 6684). We used both 18F-FMISO intensity metrics (T/Bmax, HV, SUV,
SUVmax, SUVpeak) and assessed radiomic measures that determined first-order (histogram), second-order, and
higher-order radiomic features of 18F-FMISO uptake distributions. A multivariate model was developed that
included age, HV, and the intensity of 18F-FMISO uptake. HV and SUVpeak were both independent predictors of
outcome for the combined data set (P < .001) and were also found significant in multivariate prognostic models
(P < .002 and P < .001, respectively). Further model selection that included radiomic features showed the addi-
tional prognostic value for overall survival of specific higher order texture features, leading to an increase in rela-
tive risk prediction performance by a further 5%, when added to the multivariate clinical model..
INTRODUCTION
Evolving and immature tumor vasculature can lead to chronic tis-
sue hypoxia, which is associated with resistance to radiotherapy
and chemotherapy in malignant gliomas, leading to treatment
failure and recurrence (1). Chronic hypoxia in patients with glioma
has been quantified by using 18F-fluoromisonidazole (18F-FMISO)
positron emission tomography (PET) imaging. This tracer is irre-
versibly reduced and trapped when the level of O2 is below
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3mmHg—the threshold for the oxygen enhancement effect of ion-
izing radiation (2). Several studies have shown that metrics of
brain tumor hypoxia measured by 18F-FMISO PET were associated
with time-to-progression (TTP) and/or overall survival (OS) (3–6).
Previous studies at the University of Washington (UW) of 22
patients imaged with 18F-FMISO PET following surgical resection
and before radiotherapy with concomitant chemotherapy showed
that the maximum 18F-FMISO tissue–blood ratio (T/Bmax) and
the hypoxic volume (HV) were associated with shorter OS and TTP
(4). However, in a multicenter clinical trial of 42 patients imaged
at a similar time point [ACRIN 6684 (5)], T/Bmax and HV were not
found to be prognostic, although SUVpeak (defined as the average
SUV from a 1-cm-diameter circular region centered on the tumor
voxel with greatest activity) predicted OS at 1year (OS-1) (5). The
current analysis considered both the UW and ACRIN 6684 study
cohorts with a view to examining differences in the analytical
results, and to also explore the utility of agnostic measures of 18F-
FMISO uptake using radiomic features to further assess patient
risk on the combined cohort of patients.
METHODOLOGY
Patient Characteristics
The study consisted of 2 cohorts of newly diagnosed patients
with high-grade glioma imaged with 18F-FMISO PET after histo-
pathological diagnosis and before initial standard treatment of
radiation with concomitant chemotherapy. For the UW cohort,
30 patients (27 WHO grade IV glioblastoma multiforme and
3 WHO grade III anaplastic astrocytoma; median age, 58years
[range, 32 to 77], females, 9; and males, 21) underwent 18F-
FMISO imaging studies after surgical resection and before stand-
ard treatment (see online supplemental Table S1). Patients were
selected and recruited by an experienced neuro-oncologist at the
UW-affiliated hospital system on the basis of histopathologic di-
agnosis, clinical performance status, and presence of residual tu-
mor volume on postsurgical contrast-enhanced T1 magnetic
resonance imaging (MRI). Signed informed consent, as approved
by the respective Investigational Review Boards and Radiation
Safety Committees, was obtained for all patients before 18F-
FMISO imaging. All UW patients were followed through periodic
clinical evaluations that included Karnofsky Performance Status
(KPS) and routine contrast-enhanced MRI surveillance for tumor
progression and OS. Tumor progression was determined by
RANO criteria for high-grade glioma (7). The majority of these
patients (28 out of 30) were included in previous reports examin-
ing the relationship of 18F-FMISO imaging for the prediction of
TTP and OS (4, 8).
The second cohort (n =42) was recruited through the
American College of Radiology Imaging Network (ACRIN) 6684
trial from 11 participating academic sites including UW, and the
patients included in the cohort had histopathologically proven,
newly diagnosed glioblastoma multiforme. The trial was approved
by the institutional review boards at all participating sites. Before
enrollment, all patients signed an informed consent document.
Eligible patients had undergone surgical resection before planned
standard-of-care treatment of radiation with chemotherapy. In
addition, patients could receive investigational agent(s) at any
time during the clinical trial. Study candidates were required to
have evidence of residual tumor following surgery based on MRI
imaging, although the minimal amount of residual tumor was not
specified and, unlike the UW cohort, the presence of contrast-
enhancement was not required. The ACRIN protocol thus had
much less restrictive inclusion criteria. Other key patient charac-
teristics included a median age of 60 years (range, 30–77years),
with 15 females and 27 males. Patients were followed every
3months for tumor progression and survival for a minimum of at
least 1 year or until death (median follow-up period until death,
227days; range, 74–1034days), while the patients in the UW
group was followed continuously until death and therefore had a
longer follow-up. Eleven of the 42 ACRIN patients were alive at
the end of the study the follow-up period, which terminated
12months after the last study patient was imaged. Routine clini-
cal parameters considered for statistical analysis included age,
gender, and KPS.
Scanner Qualification
The UW tomography (GE Advance, GE Medical Systems,
Waukesha, WI) was calibrated on a quarterly basis for conversion
of counts to Becquerel per milliliter using the ACR flood phantom
containing known activities of 18F imaged separately from a
patient and reconstructed using identical parameters as patient
emission images. Sample aliquots of the flood phantom were
used to cross-calibrate the gamma well counter (Packard COBRA
II, Meriden, CT) where patient blood samples were assayed to
determine 18F concentration. For the ACRIN study participants
(11 institutions), PET/computed tomography (CT) scanners (GE
Discovery STE, GE Discovery RX, GE Discovery LS, Siemens
ECAT Exact HRþ, Siemens Biograph 40, and Siemens Biograph
64) were prequalified by ACRIN using ACR flood phantom scans
of known activity and sample patient images and every 2 years
following initial accreditation. The phantom scans required
reconstruction with identical parameters as patient emission
images. Scanners were required to undergo cross-calibration to
their local gamma well counter (Packard, Perkin-Elmer, Capintec,
Beckman, Baird Atomic) at each participating center for deter-
mining blood activity within a week of patient scanning. Cross-
calibrations were done at the time of scanner calibration by
counting 1-mL aliquots from the calibration phantom following a
standardized protocol developed by UW for ACRIN. All qualifica-
tion data were centrally reviewed. One scanner, in which 3
patients were enrolled, was a prototype Siemens brain MR/PET
scanner (no model number) that could not be calibrated with a
head coil in place.
Radiosynthesis
18F-FMISO was initially prepared at UW using the glycidyl tosyl-
ate method (9), and then changed to the method developed by
Lim (10) as modified by Adamsen (11). In all cases, the same puri-
fication by high-performance liquid chromatography was used.
The product-specific activity ranged from 37 to 74 GBq/mmol at
the time of injection with >98% radiochemical purity. 18F-
FMISO was administered by venous injection of a 10-mL solution
of isotonic saline containing <10% (v/v) ethanol USP. The aver-
age injected dose for the UW studies was 259 MBq (range, 218–
350 MBq). Early studies were done under Radioactive Drug
Research Committee, but the majority was performed under
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Investigational New Drug approval. The ACRIN patients’ radio-
tracer doses were supplied by local production of 18F-FMISO or
through Cardinal Health with product characteristics specified by
the NCI-held IND (#76042). High-performance liquid chromatog-
raphy purification was not required. The mean injected dose was
237 MBq (range, 185–285 MBq).
PET Imaging Acquisition
For both cohorts, imaging with 18F-FMISO PET was performed at
a clinically relevant time after surgical tissue confirmation of
GBM diagnosis and within 2 weeks before the start of conven-
tional therapy. After patient immobilization, venous lines were
established in each arm, one for tracer injection and the other for
blood sampling. At UW, this was followed by either a 25-minute
transmission scan for the GE Advance or for the ACRIN cohort, a
low-dose CT scan for PET/CT scanners. For both cohorts, static
20-minute 18F-FMISO PET emission scans were acquired in 3-
dimensional, high-resolution mode starting 110min after
injection (mean, 118; range 90–155 minutes; n = 72) of 18F-
FMISO. Three venous blood samples were acquired at 5, 10, and
15minutes after scan initiation for quantitative assessment of
hypoxia status by normalizing tissue uptake to the blood concen-
tration as previously described (8). Averaged blood activity was
decay-corrected to the injection time and converted to the same
units as the scanner (Bq/mL).
Image Reconstruction
UW 18F-FMISO PET emission images were reconstructed by 3D-
filtered backprojection (12) with corrections for attenuation,
scatter, random events, dead time, and sensitivity, and these
resulted in an in-plane spatial resolution of 2.34mm with a post-
reconstruction 6-mm Hanning filter. Most ACRIN studies (39out
of 42) were scanned on PET/CT scanners, which used CT-based
attenuation correction. A prototype Siemens brain MR/PET scan-
ner used an estimated attenuation map based on the magnetic
resonance (MR) signal (13). Reconstruction of emission images
for the ACRIN studies used various iterative 3D techniques (3-
dimensional iterative reconstruction method [3D IR], ordered
subset expectation maximization reconstruction method [OSEM],
point spread function reconstruction method [PSF]), wherein
postreconstruction filter sizes ranged from 2 to 6 mm and recon-
structed in-plane image resolution varied between 1.25 and 6
mm with corrections for attenuation, scatter, random events,
decay, deadtime, and sensitivity (see online supplemental Table
S2). Tomography sensitivity was calibrated as described in afore-
mentioned sections.
Image Analysis
For the ACRIN cohort, 18F-FMISO images were analyzed at UW
by an experienced team that performed analysis of the original
UW cohort and served as the central analysis laboratory for
the ACRIN 6684 18F-FMISO PET studies. Images acquired with
18F-FMISO PET were decay-corrected to the time of radiotracer
injection and converted to SUV units by normalization of the
emission image to the recorded dose and patient weight.
Traditionally, volumes of interest (VOIs) were either segmented
from the contrast-enhancing volumes on the MR T1þ contrast
images and dilated by several voxels or manually constructed on
the 18F-FMISO image based on areas of 18F-FMISO tracer uptake
(4). Both methods proved adequate for routine extraction of 18F-
FMISO uptake information but proved inadequate for radiomic
texture feature extraction. Therefore, VOIs over tumor were seg-
mented from either coregistered Gd-enhanced MRI fluid-attenu-
ated inversion recovery images or T2-weighted images obtained
within 2weeks of PET image acquisition, and before conven-
tional therapy. Because 18F-FMISO is a freely diffusible tracer
(14) and tumor hypoxia may exist beyond the margins of Gd-
enhancement on MRI, each tumor VOI was segmented to include
the entire area of abnormal fluid-attenuated inversion recovery
signal hyperintensity taking care not to include postsurgical
changes such as the resection cavity and extra-axial fluid collec-
tions. An experienced neuroradiologist reviewed each MRI-based
tumor volume for all patients. The segmented tumor VOI was
then applied to the 18F-FMISO PET SUV image using PMOD soft-
ware (PMOD Tech., Version 3.8, Zurich CH) for data extraction.
Owing to the relatively large size of the MRI-segmented tumor
VOIs (4 cc–750 cc), partial volume correction was not required. In
addition, a circular 1-cm-diameter SUVpeak region of interest
was centered over the hottest voxel in the tumor. Extracted
image data from 18F-FMISO scans were normalized using the
average measured blood activity (Bq/mL) during the scan to pro-
duce tissue–blood ratio (T/B) values for all voxels in each image
slice. The pixel with maximum T/B value (T/Bmax) and the
hypoxic volume (HV) of voxels above the T/B threshold of 1.2,
indicating significant hypoxia, were determined to quantify
the volume of tissue hypoxia in each tumor region (4). To include
the 3 patients scanned on the MRI/PET scanner, their image
data were scaled by the average ratio of blood to cerebellar
cortex activity, as these values are highly correlated (8) for
standard PET imaging. Conventional PET and hypoxia param-
eters extracted from tumor regions included VOI volume,
SUVmax, SUVmean, SUVpeak, T/Bmax, HV, and TLH (total
lesion hypoxia = SUVmean  VOI).
Radiomic Analysis
We evaluated a set of radiomic features assessing texture
characteristics of the hypoxia distribution of the 72 patients
with brain cancer from the 2 cohorts who had 18F-FMISO PET
studies with concurrent blood sampling. An adaptive thresh-
olding method (30% of SUVmax) was then applied to the
segmented tumor VOIs, yielding volumes that were restricted
from void regions, but including voxels with 18F-FMISO uptake
(Figure 1). Preprocessing of 18F-FMISO emission images for
radiomic analysis included spatial normalization of the image
data and tumor VOI segmentation mask, based on the segmenta-
tions used for standard analyses noted above, and interpolated in
3 dimensions at the lowest resolution of the 2 cohorts (1mm) via
trilinear interpolation. The exploratory investigation on the asso-
ciation to outcome considered the following biomarkers detailed
in the Image Biomarker Standardization Initiative (IBSI) refer-
ence manual (15) for analysis: 12 first-order statistical variables
reflecting intensity (IBSI Section 3.4), 20 histogram features of
the discretized uptake values (IBSI Section 3.5), 22 texture fea-
tures of the gray-level co-occurrence matrix (GLCM) (IBSI
Section 3.6), 16 GLRLM-based features emphasizing discretized
images with long-run lengths, or sequences of voxels with the
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same discretized intensity (IBSI Section 3.7) and 16-GLSZM-
based features evaluating entropy (or uniformity) in the distribu-
tion of groups of connected voxels with the same discretized
intensity (IBSI Section 3.8). Following the guidelines of
Vallières at al. (16) on responsible radiomics, the online sup-
plemental online data provides a description of the radiomic
extraction process and ontology of the radiomic features used
in this report. An open-source software implementation of
radiomic features in R (mia 1.0.4, https://github.com/ericwol/
mia) was used for radiomic quantitation of the 18F-FMISO
uptake distribution. Certain features based on the GLCM (eg,
contrast, entropy, dissimilarity, homogeneity) have been
shown to have high predictive value for PET imaging (17–19).
In total, there were 97 variables for each patient that were con-
sidered for model selection—11 conventional clinical and PET
variables and 86 radiomic PET features.
Statistical Analysis
Comparisons between cohorts for parameters such as uptake
time and the 97 other variables were made using a 2-sample
Wilcoxon (Mann–Whitney) test for equal distributions (20). To
examine the relationship of clinical, PET, and textural bio-
markers to OS, the following methods were used.
Univariate Model. Univariate Cox proportional model analy-
ses were applied to all variables on each cohort and the combined
cohort to assess the statistical significance of each variable sepa-
rately for OS prognosis. In these analyses, significance levels
were set at the 5% level with Bonferroni correction to limit the
risk of a type 1 error (false positives).
Multivariate Model. Multivariate prognostic modeling was
performed in 2 steps: first to explore the prognostic value of a
model that comprises conventional clinical variables, thereby
selecting the most parsimonious base reference clinical model,
before evaluating the potential for prognostic improvement by
adding radiomic features.
In the first step, we performed optimal subset selection by
evaluating all possible Cox proportional hazards models com-
prising combinations of the clinical variables to identify the AIC
(Akaike information criterion)-minimizing (21) model from only
conventional clinical and PET variables (see online supplemental
Figure S1). The analysis resulted in a base clinical model with a
parameter combination of age, HV of the tracer, and the intensity
of the tracer (T/Bmax and SUVpeak).
In the second step, preliminary feature elimination was per-
formed to remove radiomic variables that had a strong correla-
tion with other clinical or radiomic variables. We eliminated
features with a Pearson correlation >80% in absolute value.
Forward stepwise selection (22) was then carried out to yield a
second multivariate Cox model. This search allowed selection in
both forward and backward directions of any remaining conven-
tional or radiomic variables to the base clinical model from the
first step. This step tested the additional prognostic benefit from
radiomic features.
The hazard ratio along with its 95% confidence interval and
associated P-value based on Wald’s statistic were reported for
the Cox models. Prognostic significance was assessed by boot-
strapped median P-value (using 1000 bootstrap resamples), and
considered both at the 5% significance level and with Bonferroni
correction. The likelihood ratio test (LRT) was used to confirm
statistical significance of the addition of textural variables to the
base clinical model (23, 24). The concordance index of the multi-
variate prognostic model assessed potential gain in predictive
performance over the base clinical model. Kaplan–Meier survival
curve estimates from diagnosis to time-to-death were generated.
All analyses were done using R (CRAN R-Project; https://cran.r-
project.org).
Figure 1. Image segmentation for data extraction. The tumor region is segmented from the magnetic resonance imag-
ing (MRI) fluid-attenuated inversion recovery (FLAIR) (blue line) as a region of hyperintensity (A). The region is applied to
the 18F-fluoromisonidazole (18F-FMISO) standard uptake value (SUV) image (B). Adaptive thresholding of the 18F-FMISO
SUV image yields the tumor volume for radiomic analysis that avoids regions of low uptake (C).
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RESULTS
Considering patient characteristics of the 2 cohorts, the UW one
had lower KPS (mean, 80; range, 60–100 KPS) than the ACRIN
cohort (mean, 87; range, 70–100 KPS; Wilcoxon test, P= .028).
The uptake time between injection and scanning for the UW
cohort (mean, 128minutes; range, 100–155 minutes) was longer
than the ACRIN cohort on the average (mean, 111minutes; range,
90–145minutes; Wilcoxon test, P< .001). While the UW group
had a combination of grades III and IV patients, removing grade III
patients did not yield significantly different results. Methodological
differences in attenuation, reconstruction algorithm, and filter size
varied significantly between cohorts (see online supplemental Table
S1). Conventional PET uptake parameters for 18F-FMISO (SUVmax,
SUVpeak, T/Bmax, and HV) appear in Table 1. A notable difference
in distribution between UW and ACRIN cohorts was observed for
only KPS, on the basis of Bonferroni-corrected Wilcoxon tests. At
the 5% significance level, without Bonferroni correction, only one
other variable (run-length nonuniformity, a GLRLM-based texture
feature) yielded a difference in cohort distributions (P = .002).
Reconstruction methods are known to have a substantial effect on
radiomic features (25, 26), and there were clearly reconstruction dif-
ferences between the 2 cohorts.
Univariate Analysis
PET parameters were assessed on the basis of overall patient sur-
vival status at last follow-up, including censoring information.
Univariate Cox proportional modeling combining the 2 cohorts
showed that 24 variables were significant without Bonferroni
correction, but only 9 were significant for prognosis at the 5%
significance level with Bonferroni correction (Table 2). In partic-
ular, age, SUVpeak, and HV were all independent predictors of
outcome in the combined data set after Bonferroni correction
(P< .001 for all). Comparing the results between the 2 data sets,
the UW cohort had all 9 variables from Table 2 remain significant
at the 5% significance level, with HV and SUVpeak both remain-
ing independent predictors after Bonferroni correction. Six of the
9 variables were significant independent predictors at the 5% sig-
nificance level in the ACRIN group (Table 2), where HV,
SUVpeak, and GLCM energy were not significant.
Multivariate Analysis
Following selection of the best parameter subset for model com-
position, the most parsimonious base conventional parameter
Cox model with optimal AIC value included age, HV, SUVpeak,
and T/Bmax, and is summarized in Table 3. All 4 variables in this
model were statistically significant prognostic markers at the 5%
significance level, with HV and age remaining significant after
Bonferroni correction, using threshold significance level 0.05/
Pclinical< 0.005, where Pclinical = 11 clinical variables.
The second multivariate prognostic model obtained by
extending the base conventional model is presented in Table 4. It
illustrates the enhanced prognostic potential obtained by adding
texture features to the base model. Although clinical variables
were permitted in the model selection procedure, texture features
were selected over conventional variables by the more objective
stepwise selection algorithm. This supports a potential benefit in
introducing texture analyses for postresection risk characteriza-
tion in glioma. The likelihood ratio test confirmed the statistical
significance (P < .010) of the additional contribution of this set
of texture variables. We observed a reasonably high concordance
index of 77.4% for the model of Table 2. This index measures the
pairwise probability of assessing a lower patient risk, based on










Mean 3.15 2.53 2.13 28.40
SD 1.11 1.04 0.71 35.51
Median 2.94 2.15 2.00 12.28
Max 6.53 5.64 4.26 131.90
Min 1.85 1.34 1.27 1.59
ACRIN
Mean 3.20 2.49 2.10 13.39
SD 1.14 0.84 0.75 11.49
Median 2.96 2.26 2.02 10.42
Max 6.26 5.00 4.14 41.18
Min 1.80 1.45 0.95 0.00
ALL
Mean 3.18 2.51 2.11 19.64
SD 1.12 0.92 0.73 25.43
Median 2.94 2.24 2.00 11.39
Max 6.53 5.64 4.26 131.90
Min 1.80 1.34 0.95 0.00
18F-FMISO PET uptake parameters for the single-center UW, multicenter ACRIN 6684 and the combined cohorts of all patients. T/Bmax is the maximum
tumor voxel normalized by the blood activity at the time of scanning, and HV refers to the hypoxic volume of pixels above the T/B threshold of 1.2 indi-
cating significant hypoxia.
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the model, given the longer survival time, and is equivalent to
the AUC value in an ROC analysis. The addition of the texture
features to the base clinical model led to an increase in relative
risk prediction performance, from 72.2% to 77.4%.
Figure 2 shows the Kaplan–Meier OS curve estimates
obtained from the base (dashed red lines) and extended (solid
blue lines) multivariate Cox models. Dichotomous separation of
the combined cohort into higher- and lower-risk groups (lower
and higher curves respectively) was obtained by maximizing the
statistical separation in terms of the log-rank test statistic. The
separation of high-risk from low-risk patients was statistically
significant for both models (log-rank test, P< .001).
DISCUSSION
We investigated the association of 18F-FMISO PET hypoxia pa-
rameters with survival between a single-center (UW) cohort and
a multicenter (ACRIN 6684) cohort. Although both studies
showed prognostic value for 18F-FMISO, the 2 studies found the
association with different measures of tracer uptake. Previous
results on a subset of 22 patients of the UW cohort showed that
age, T/Bmax, and HV were significant in predicting OS (4) in uni-
variate analyses. A similar result for OS was shown here using a
larger UW cohort of 30 patients (Table 2), while in the multicen-
ter ACRIN cohort, only SUVpeak was significant in univariate
analyses for OS-1. Although all patients in both studies had
pathologically proven brain tumors imaged before conventional
therapy, the 2 cohorts appear different with respect to traditional
18F-FMISO uptake parameters, particularly HV. A potential ex-
planation of the differences between the 2 individual cohorts
most likely lies in patient selection. The UW cohort had larger
hypoxic volumes of 18F-FMISO and incidentally had lower KPS,
indicating greater disease involvement, although there were no
differences in postsurgery contrast-enhancement volume on MRI
T1 between the UW cohort and the ACRIN cohort. Unlike the UW
group, a few of the ACRIN patients had no 18F-FMISO uptake
and therefore no measurable hypoxic volume. For example,
hypoxic volumes were <4 cc in nearly 30% (12 out of 42) of
patients in the ACRIN cohort compared with in 7% (2 out of 30)
of patients in the UW cohort. Low residual tumor volume at the
time of 18F-FMISO imaging may not permit adequate assessment
of hypoxia by any measure, such as tracer distribution, intensity,
or structural characteristics of spatial uptake distribution. A
smaller HV limits image count statistics in the ACRIN data set
and along with the added noise of variability in cross-calibration
where multiple sites differ in scanner, image reconstruction,
counters, and blood sampling/counting skill levels may well
explain why T/Bmax and HV did not work better for univariate
ACRIN data set analysis. In addition, the T/B threshold of 1.2 that
defines the volume of hypoxic voxels within the tumor was
developed using filtered backprojection image data, and could
well be different for images using an estimation reconstruction
analysis.
Heterogeneity of treatment in the ACRIN cohort versus
relatively uniform treatment in the single-center UW study may
also affect study outcome. The ACRIN cohort had many patients
with alternative therapies (Lomustine, Paclitaxel, Poliglumex,
Selinexor, Vorinostat, Dasatinib, Carmustine, Bevacizumab) dur-
ing and following conventional therapy; the UW cohort had
Table 2. Univariate Analysis Hazard Ratios (P-value) E
Parameter Combined ACRIN Cohort UW Cohort
Age 1.94 (<.001) 2.45 (.002) 1.58 (.017)
SUVpeak 1.71 (<.001) 1.46 (.070) 2.24 (.001)
HV 1.80 (<.001) 0.98 (.957) 1.85 (.001)
SUVmean 1.87 (<.001) 2.03 (.001) 1.70 (.004)
Median 1.82 (<.001) 2.36 (.001) 1.53 (.012)
p10 1.71 (<.001) 2.08 (.006) 1.48 (.026)
p90 1.71 (<.001) 1.64 (.002) 2.02 (.001)
GLCM Energy 1.73 (<.001) 1.27 (.451) 1.73 (.001)
RMS 1.88 (<.001) 1.99 (.001) 1.72 (.003)
Variables that were found statistically significant in univariate survival analyses after Bonferroni correction, with associated P-values for the combined,
ACRIN, and UW cohorts respectively. P-values in bold indicate significance with respect to the Bonferroni correction threshold of 0.05/97 = 0.0005.
Median, p10, p90, and RMS, respectively, correspond to the sample median, 10th and 90th percentiles, and root mean square (quadratic mean) of the tu-
mor SUV values.
Table 3. Base Multivariate Cox Model
Analysis
Variable Effect HR (95% CI) Median P
Age 0.74 2.10 (1.52, 2.91) <.001
HV 0.54 1.72 (1.23, 2.41) .002
SUVpeak 0.66 1.93 (1.18, 3.17) .006
TBmax 0.50 0.61 (0.39, 0.96) .023
The base multivariate Cox model was comprised of 4 conventional
variables, showing predictor effects, associated hazard ratio (HR) with
associated 95% confidence interval (CI), and bootstrap median P-val-
ues obtained from 1000 bootstrap resamples. All 4 variables are sig-
nificant at the 5% level; P-values in bold indicate significance after
bonferroni correction (P< .005). This model has a concordance index
of 0.722.
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fewer agents (Carboplatin, Irinotecan, Bevacizumab) and they
were used only after conventional therapy had been completed.
Treatments during and after 18F-FMISO imaging may modulate
the time to progression and potentially delay death, altering the
survival outcome variables. Notable differences between the
early survival characteristics of the 2 cohorts, the degree of tumor
burden as observed with 18F-FMISO HV, and the inclusion of al-
ternative therapies may partially explain these findings. Both
Table 4. Extended Multivariate Cox Model Analysis E
Variable Effect HR (95% CI) Median P
Age 0.84 2.31 (1.65,3.25) <.001
HV 0.67 1.95 (1.28, 2.97) .006
SUVpeak 0.97 2.63 (1.52, 4.56) .001
TBmax 0.75 0.47 (0.28, 0.80) .010
HIST CoVa 1.29 3.65 (1.72, 7.73) .001
HIST QCOD 0.59 0.55 (0.36, 0.86) .015
HIST Kurtosis 0.55 0.58 (0.34, 0.98) .048
GLRLM Long runs emphasis 1.26 0.28 (0.14, 0.58) .001
GLSZM Zone size entropy 0.74 2.10 (1.18, 3.71) 0.020
GLSZM Low gray-level zone emphasis 0.41 1.51 (0.94, 2.45) 0.110
Extended multivariate Cox model obtained by selecting additional variables (conventional or radiomic) to the base model, showing predictor effects,
associated hazard ratio (HR) with associated 95% confidence interval (CI), and bootstrap median P-values obtained from 1,000 bootstrap resamples.
Nine of the 10 variables are significant at the 5% level; P-values in bold indicate significance after Bonferroni correction. This model has a concordance
index of 0.774. The likelihood ratio test confirmed the significant contribution (P = .010) of the additional set of radiomic variables.
a HIST CoV, HIST QCOD, and HIST Kurtosis, respectively refer to the coefficient of variation (CoV), quartile coefficient of dispersion (QCOD), and kurtosis
of the histogram of discretized uptake values; these 3 features evaluate various aspects of discretized uptake distribution variability. GLRLM long runs
emphasize discretized images with long-run lengths (ie, sequences of voxels with the same discretized intensity). GLSZM zone size entropy evaluates en-
tropy (or uniformity) in the distribution of groups of connected voxels with the same discretized intensity. GLSZM low gray-level zone emphasis high-
lights discretized images containing more low-intensity regions.
Figure 2. Survival analysis for the base and
extended multivariate models on the combined
cohorts. Kaplan–Meier analysis of overall sur-
vival (OS) with stratification into lower- and
higher-risk groups (the higher and lower curves,
respectively) based on maximized statistical
separation in terms of the log-rank test statistic
(P< .001), for the base 4-variable clinical
model comprised age, hypoxic volume (HV), T/
Bmax (maximal activity voxel in a tissue region
normalized by the blood activity) and SUVpeak
(average SUV from a 1-cm circular ROI centered
over the hottest voxel; dashed red lines), and its
extension using additional radiomic features
(solid blue lines). The figure shows how the latter
model led to different patient classification.
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independent studies were carried out on limited sample sizes, and
as such, differences in (or lack of) significance for some of the
variables may also be a direct consequence of low statistical
power.
The present analysis on the aggregated cohort highlighted
the preserved significance of both sets of markers from each
cohort. Each of the 4 variables in the multivariate base model of
Table 3 was a statistically significant jointly prognostic marker
at the 5% significance level. The multivariate model applied to
the combined cohort thus assesses complementary aspects of
18F-FMISO uptake by including the tracers’ overall distribution
(HV) and intensity of uptake (SUVpeak and T/Bmax).
Texture features, such as GLCM entropy and other radiomic
measures could improve the prediction of patient outcome. The
addition of 6 radiomic variables, identified via a formal statistical
stepwise selection process, to the initial 4-variable clinical model
led to an added 5% in concordance index, and their inclusion
contributed to a multivariate Cox proportional hazards model
that was deemed statistically significant (P< .001).
LIMITATIONS
The modest sample size and constraints on follow-up in this
study are important to highlight. These issues arose owing to the
limited access to FMISO radiotracer imaging for patients with gli-
oma during the period following pathological confirmation and
before conventional therapy. ACRIN funding limited patient fol-
low-up to be a minimum of 1 year. At the end of the study, 9
patients were alive and thereafter lost to follow-up, and thus
were censored.
Selection of the prognostic multivariate models presented in
Tables 3 and 4 could be performed in a number of different ways.
The base multivariate clinical model of Table 3 was selected
using conventional best-subset selection, an exhaustive compar-
ison of all possible models on the basis of some goodness-of-fit
criterion adjusted for model dimension. We use AIC for this test,
as it is one of the most commonly used metrics and a reasonable
choice considering the relatively small number of candidate
variables. The extended model of Table 4 is subject to selection
bias, as it was constrained to include the 4 conventional variables
of the base model of Table 3. As such it should be validated on an
independent 18F-FMISO PET-imaged glioma cohort. The modest
sample size prevented the ability to carry out convincing training
and test validation. A much larger cohort might have facilitated
such an approach and thereby reduced the lingering risk of opti-
mistic bias associated with retrospective analysis of small data
sets. However, our models can be considered as demonstrations
of prognostic potential, as an illustration of the opportunity for
potential prognostic enhancement provided by radiomic analysis
of 18F-FMISO imaging data when combined with standard clini-
cal models.
CONCLUSIONS
Differing significance of quantitative metrics for 18F-FMISO
uptake resulted between a single-center cohort and a multicenter
cohort of glioma patients for the assessment of hypoxia using
18F-FMISO PET before combined radiotherapy and chemotherapy.
These may be explained by single-center patient selection bias for
patients in the UW cohort with larger tumors that allow adequate
assessment of hypoxia and by a substantial subset of multicenter
patients with low or no HV in the other cohort. The present analy-
sis on the aggregated cohort highlighted the preserved significance
of 18F-FMISO PET markers from both sets. Multiparametric model-
ing on the combined cohort showed that all of SUVpeak, HV and
T/Bmax together with age have a significant predictive value
when combined in a multivariate prognostic model. Our results
also showed that adding selected radiomic features to this prog-
nostic model further increased predictive performance for the
combined group of patients and might be considered in future
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